- Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial
- Moleculin to Present at the Virtual Investor Pitch Conference
- Moleculin to Participate in the Virtual Investor Lunch Break Series
- Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
- Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)
- Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
- Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast
- Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
- Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024
More ▼
Key statistics
On Wednesday, Moleculin Biotech Inc (MBRX:NAQ) closed at 3.63, 8.36% above its 52-week low of 3.35, set on Jun 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.50 |
---|---|
High | 3.63 |
Low | 3.43 |
Bid | 3.36 |
Offer | 3.74 |
Previous close | 3.57 |
Average volume | 12.14k |
---|---|
Shares outstanding | 2.31m |
Free float | 2.20m |
P/E (TTM) | -- |
Market cap | 8.39m USD |
EPS (TTM) | -12.94 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 17:23 BST.
More ▼